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Abstract 
Considering the prevalence of cardiovascular disease in public health and the limited validated 
therapeutic options, this study aimed to find novel compounds targeting the angiotensin II type 1 
receptor, accepted as a therapeutic target in cardiovascular disease. A small library consisting of 
89 compounds from 39 Chinese herbs was profiled using a cell-based calcium mobilization assay 
which was developed and characterized for high-throughput screening. [6]-Gingerol derived 
from Zingiber officinale Roscoe (ginger) was identified as a novel angiotensin II type 1 receptor 
antagonist, with an IC50 value of 8.173 µM. The hit was further tested by a specificity assay 
indicating that it had no antagonistic effects on other evaluated GPCRs, such as endothelin 
receptors. The major ingredient of ginger, [6]-gingerol, could inhibit angiotensin II type 1 
receptor activation, which partially clarified the mechanism of ginger regulating blood pressure 
and strengthening heart in the cardiovascular system. 
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